Open AccessEfficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
Author(s) -
Manuel Caitano Maia,
Allan Andresson Lima Pereira,
Luís Alberto de Pádua Covas Lage,
Natália Moreno Perez Fraile,
Victor Van Vaisberg,
Guilherme Konishi Kudo,
Romualdo BarrosoSousa,
Diogo Assed Bastos,
Carlos Dzik
Publication year - 2018
Publication title -
journal of global oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.002
H-Index - 17
ISSN - 2378-9506
DOI - 10.1200/jgo.2016.007807
Subject(s) - medicine , docetaxel , prostate cancer , oncology , castration , cancer , hormone
Limited data are available about the tolerability and clinical outcomes of elderly patients with metastatic castration-resistant prostate cancer (mCRPC) who are treated with docetaxel. We evaluated the efficacy and safety of docetaxel as first-line chemotherapy for patients with mCRPC who were treated in our institution.